Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization
Feb
10
2015
Clinical Trial Data: Shared Resource or Private Property? Faegre Drinker
Feb
10
2015
Important Developments in FDA Regulation of Software, Including Mobile Apps Covington & Burling LLP
Feb
10
2015
Exploring Indian Country Marijuana Godfrey & Kahn S.C.
Feb
10
2015
Seventh Circuit Says Assignment Law Not a Basis for FCA Suit (False Claims Act Suit) McDermott Will & Emery
Feb
10
2015
China Struggles With Food Safety Covington & Burling LLP
Feb
9
2015
Out-of-Market Divestiture Required to Resolve Competitive Concerns McDermott Will & Emery
Feb
9
2015
FDA Issues Draft Guidance on Combination Product Manufacturing Covington & Burling LLP
Feb
9
2015
Alcohol & Tobacco Tax & Trade Bureau (TTB) Publishes Semi-Annual Regulatory Agenda with Plans and Goals for the Coming Year McDermott Will & Emery
Feb
7
2015
21st Century Cures Discussion Draft Act Proposes Changes to Medical Device Regulation Covington & Burling LLP
Feb
6
2015
Testosterone Replacement Clinic Agrees to Pay the Government $1.6 Million for Alleged Medicaid Fraud Tycko & Zavareei LLP
Feb
6
2015
FDA Issues Draft Guidances Aimed at Reducing Oversight of Low Risk General Wellness Products and Medical Device Accessories Greenberg Traurig, LLP
Feb
6
2015
Nice Insight on Trends and Expectations for Outsourcing in the Biopharmaceutical Industry Morgan, Lewis & Bockius LLP
Feb
6
2015
Mixing Things Up: Let’s Talk Recipes, Part One of a Four-Part Series on Copyright Lewis Roca Rothgerber LLP
Feb
6
2015
Is Compulsory Licensing of Generic Medicines Coming to the Russian Federation? Michael Best & Friedrich LLP
Feb
5
2015
Consider Non-Regulatory Alternatives, Small Business Panel on Infectious Diseases Tells OSHA Jackson Lewis P.C.
Feb
5
2015
FDA Requests Comments on WHO Recommendation to Classify Two Common Industrial Solvents as Psychotropic Substances Beveridge & Diamond PC
Feb
5
2015
New Rule on Medicare Reimbursement for Chronic Care Management Services McBrayer, McGinnis, Leslie and Kirkland, PLLC
Feb
5
2015
President’s Budget Includes Funding for Precision Medicine Initiative Covington & Burling LLP
Feb
4
2015
FDA Issues Draft Guidance on General Wellness Devices and on Medical Device Accessories McDermott Will & Emery
Feb
4
2015
New York Targets Popular Supplements: Whistleblower Mahany Law
Feb
3
2015
Filthy Pharma – Whistleblowers and Current Good Manufacturing Practices Mahany Law
Feb
3
2015
Are Lower Cost Drugs Less Effective? It May Depend on the Patient’s Perspective. Epstein Becker & Green, P.C.
Feb
2
2015
FDA Issues Draft Guidance on Medical Device Accessories Barnes & Thornburg LLP
Feb
2
2015
EMA Transparency Policy – EMA Launches Public Consultation On The Publication Of Information Under The New EU Clinical Trials Regulation Covington & Burling LLP
Jan
30
2015
Federal Circuit Upholds PTO Refusal to Withdraw Unauthorized Terminal Disclaimer McDermott Will & Emery
Jan
30
2015
Practice Considerations Post Teva v. Sandoz Sterne, Kessler, Goldstein & Fox P.L.L.C.
Jan
30
2015
No Declaratory Jurisdiction Without Biosimilarity Application on File with FDA McDermott Will & Emery
Jan
30
2015
Inherency Requires Factual Evidence that a Limitation Is Necessarily Present or Is the Natural Result McDermott Will & Emery
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins